The closing price of Exact Sciences Corp. (NASDAQ: EXAS) was $61.46 for the day, up 9.22% from the previous closing price of $56.27. In other words, the price has increased by $+5.19 from its previous closing price. On the day, 2421629 shares were traded.
Ratios:
Our analysis of EXAS’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 14.35 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 349.42. For the most recent quarter (mrq), Quick Ratio is recorded 2.07 and its Current Ratio is at 2.32. In the meantime, Its Debt-to-Equity ratio is 0.82 whereas as Long-Term Debt/Eq ratio is at 0.79.
On December 14, 2023, Guggenheim started tracking the stock assigning a Buy rating and target price of $90.
On December 13, 2023, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $95.Wolfe Research initiated its Outperform rating on December 13, 2023, with a $95 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 01 ’24 when Conroy Kevin T sold 8,271 shares for $59.32 per share. The transaction valued at 490,636 led to the insider holds 1,299,496 shares of the business.
LEVANGIE DANIEL J sold 5,000 shares of EXAS for $287,500 on Mar 01 ’24. The Director now owns 22,975 shares after completing the transaction at $57.50 per share. On Mar 01 ’24, another insider, Elliott Jeffrey Thomas, who serves as the Chief Financial Officer of the company, sold 2,412 shares for $59.32 each. As a result, the insider received 143,080 and left with 10,933 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EXAS now has a Market Capitalization of 11.16B and an Enterprise Value of 12.93B. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.46 while its Price-to-Book (P/B) ratio in mrq is 3.54. Its current Enterprise Value per Revenue stands at 5.17 whereas that against EBITDA is 441.69.
Stock Price History:
Over the past 52 weeks, EXAS has reached a high of $100.77, while it has fallen to a 52-week low of $56.05. The 50-Day Moving Average of the stock is 64.81, while the 200-Day Moving Average is calculated to be 74.54.
Shares Statistics:
EXAS traded an average of 1.96M shares per day over the past three months and 2.4M shares per day over the past ten days. A total of 181.36M shares are outstanding, with a floating share count of 179.64M. Insiders hold about 1.04% of the company’s shares, while institutions hold 89.99% stake in the company. Shares short for EXAS as of Feb 15, 2024 were 7.27M with a Short Ratio of 3.71, compared to 7.6M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.01% and a Short% of Float of 4.05%.
Earnings Estimates
The firm’s stock currently is rated by 15 analysts. On average, analysts expect EPS of -$0.47 for the current quarter, with a high estimate of -$0.17 and a low estimate of -$0.63, while EPS last year was -$0.42. The consensus estimate for the next quarter is -$0.22, with high estimates of -$0.09 and low estimates of -$0.33.
Analysts are recommending an EPS of between -$0.31 and -$1.29 for the fiscal current year, implying an average EPS of -$0.82. EPS for the following year is $0.08, with 16 analysts recommending between $0.81 and -$0.64.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 19 analysts. It ranges from a high estimate of $682M to a low estimate of $619.99M. As of the current estimate, Exact Sciences Corp.’s year-ago sales were $602.45M, an estimated increase of 4.30% from the year-ago figure. For the next quarter, 19 analysts are estimating revenue of $701.13M, an increase of 12.70% over than the figure of $4.30% in the same quarter last year. There is a high estimate of $721.08M for the next quarter, whereas the lowest estimate is $687.31M.
A total of 21 analysts have provided revenue estimates for EXAS’s current fiscal year. The highest revenue estimate was $2.87B, while the lowest revenue estimate was $2.82B, resulting in an average revenue estimate of $2.83B. In the same quarter a year ago, actual revenue was $2.5B, up 13.40% from the average estimate. Based on 20 analysts’ estimates, the company’s revenue will be $3.23B in the next fiscal year. The high estimate is $3.3B and the low estimate is $3.17B. The average revenue growth estimate for next year is up 13.80% from the average revenue estimate for this year.
